Business
Sareum notes Sierra Q2 results
Sareum notes Sierra Q2 results.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 4483I Sareum Holdings PLC 08 August 2019 \n\n \n\n\n\n(AIM: SAR)\n\n\n8 August 2019\n\n\n\n \nThe information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014\nSareum Holdings PLC \n(\"Sareum\" or the \"Company\") \nSareum notes Sierra Oncology has reported its Second Quarter 2019 Results and Published its Form 10-Q with the US SEC\nSareum Holdings PLC, the specialist small molecule drug development business notes that Sierra Oncology (\"Sierra\"), the licence holder advancing clinical cancer candidate SRA737, has announced its financial and operational results for the second quarter 2019 ended 30 June 2019. The status and recent progress made on the development of SRA737, a novel Chk1 inhibitor, is summarised in an excerpt from the statement below.\nAt the 2019 ASCO Annual meeting, Sierra reported preliminary efficacy and safety data from two ongoing clinical trials evaluating SRA737 across multiple indications, as monotherapy and when potentiated by non-cytotoxic low-dose gemcitabine (LDG). SRA737 demonstrated notable anti-cancer activity in multiple indications including a 30% Overall Response Rate in evaluable patients with anogenital cancer treated with SRA737+LDG, an indication for which the second-line metastatic setting represents a significant unmet medical need with no approved therapies and very poor life expectancy. Additionally, evaluable RAS wild-type subjects whose tumours harboured FA/BRCA gene network mutations displayed favourable outcomes across multiple indications, with an Overall Response Rate of 25%. \nDuring the second quarter, Sierra announced plans to prioritise its resources on the development of its lead candidate momelotinib and that it has launched a campaign exploring non-dilutive strategic options to support the future continued development of its portfolio of DNA Damage Response (DDR) assets, which includes SRA737.\nIn its Form 10-Q, filed with the US Securities and Exchange Commission (SEC) today, Sierra noted further information relating to the milestone payment schedule (of which Sareum is eligible to receive 27.5%) resulting from the future development of SRA737:\nAdditional milestone payments of up to an aggregate of $319.5 million may become payable to ...